← Leaderboards
Juan R Del Valle
New Mexico State University Las Cruces
$6,525,089
Attributed
$8,808,862
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,808,862 · 8
By mechanism
R01$7,599,200 · 4
R21$787,233 · 2
U54$281,029 · 1
SC2$141,400 · 1
Top collaborators
- Chih-Chi Andrew Hu9 shared
Most similar at New Mexico State University Las Cruces
Same institution · by research overlap
- Yanyan Zhang$436,800
- Manuel F Varela$1,025,908
- John R Engen$5,393,322
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsIn VitroGrowthExhibitsCellsLeadStructureIn VivoMalignant NeoplasmsApoptosisBaseResistancePhosphotransferasesChemical SynthesisSeriesDesignGenesPeptidesEvaluationPathway InteractionsAnalogAlzheimer&AposLigandsPlay
Grant awards (24)
XBP1 Inhibition and STING activation for the treatment of cancer$574,484
R01 · FY2025 · CA
A macrocyclic peptide platform for the discovery of functional tau epitopes$553,998
R01 · FY2025 · AG · contact PI
Chemical approaches to selectively target beta-rich amyloids$471,616
R01 · FY2025 · AG · contact PI
XBP1 Inhibition and STING activation for the treatment of cancer$545,760
R01 · FY2024 · CA
Chemical approaches to selectively target beta-rich amyloids$481,241
R01 · FY2024 · AG · contact PI
Chemical approaches to selectively target beta-rich amyloidosis$66,951
R01 · FY2024 · AG · contact PI
XBP1 Inhibition and STING activation for the treatment of cancer$562,994
R01 · FY2023 · CA
Chemical approaches to selectively target beta-rich amyloids$481,241
R01 · FY2023 · AG · contact PI
XBP1 Inhibition and STING activation for the treatment of cancer$589,861
R01 · FY2022 · CA
Chemical approaches to selectively target beta-rich amyloids$481,241
R01 · FY2022 · AG · contact PI
Chemical approaches to selectively target beta-rich amyloids$495,366
R01 · FY2021 · AG · contact PI
Pharmacological Blockage of XBP-1s Expression in Cancer$464,966
R01 · FY2019 · CA · contact PI
Pharmacological Blockage of XBP-1s Expression in Cancer$451,183
R01 · FY2018 · CA · contact PI
Pharmacological Blockage of XBP-1s Expression in Cancer$453,625
R01 · FY2017 · CA · contact PI
Pharmacological Blockage of XBP-1s Expression in Cancer$456,149
R01 · FY2016 · CA · contact PI
Optimization and Efficacy of Covalent Ire-1 RNase Inhibitors in CLL$207,616
R21 · FY2016 · CA · contact PI
Pharmacological Blockage of XBP-1s Expression in Cancer$468,524
R01 · FY2015 · CA · contact PI
Optimization and Efficacy of Covalent Ire-1 RNase Inhibitors in CLL$187,475
R21 · FY2015 · CA · contact PI
Targeting Akt with substrate mimetic antagonists$172,249
R21 · FY2013 · CA · contact PI
Targeting Akt with substrate mimetic antagonists$219,893
R21 · FY2012 · CA · contact PI
Synthesis of New Ligands for the Characterization of Siderophore-ExFABP Interacti$95,210
U54 · FY2009 · CA · contact PI
Synthetic Methods toward Antimicrobial tert-Alkylamino Carbocycles$141,400
SC2 · FY2008 · AI · contact PI
Synthesis of New Ligands for the Characterization of Siderophore-ExFABP Interacti$90,822
U54 · FY2008 · CA · contact PI
Synthesis of New Ligands for the Characterization of Siderophore-ExFABP Interacti$94,997
U54 · FY2007 · CA · contact PI